Eli Lilly Statistics
Total Valuation
Eli Lilly has a market cap or net worth of $759.23 billion. The enterprise value is $799.51 billion.
| Market Cap | 759.23B |
| Enterprise Value | 799.51B |
Important Dates
The next confirmed earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Aug 15, 2025 |
Share Statistics
Eli Lilly has 897.74 million shares outstanding. The number of shares has decreased by -0.18% in one year.
| Current Share Class | 897.74M |
| Shares Outstanding | 897.74M |
| Shares Change (YoY) | -0.18% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 0.16% |
| Owned by Institutions (%) | 87.95% |
| Float | 895.44M |
Valuation Ratios
The trailing PE ratio is 55.30 and the forward PE ratio is 30.51. Eli Lilly's PEG ratio is 0.92.
| PE Ratio | 55.30 |
| Forward PE | 30.51 |
| PS Ratio | 14.25 |
| Forward PS | 11.26 |
| PB Ratio | 41.41 |
| P/TBV Ratio | 115.78 |
| P/FCF Ratio | 156.30 |
| P/OCF Ratio | 69.80 |
| PEG Ratio | 0.92 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.27, with an EV/FCF ratio of 163.67.
| EV / Earnings | 57.94 |
| EV / Sales | 15.01 |
| EV / EBITDA | 32.27 |
| EV / EBIT | 34.94 |
| EV / FCF | 163.67 |
Financial Position
The company has a current ratio of 1.28, with a Debt / Equity ratio of 2.18.
| Current Ratio | 1.28 |
| Quick Ratio | 0.51 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 8.18 |
| Interest Coverage | 25.14 |
Financial Efficiency
Return on equity (ROE) is 86.29% and return on invested capital (ROIC) is 28.32%.
| Return on Equity (ROE) | 86.29% |
| Return on Assets (ROA) | 16.55% |
| Return on Invested Capital (ROIC) | 28.32% |
| Return on Capital Employed (ROCE) | 36.96% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $293,615 |
| Employee Count | 47,000 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 1.06 |
Taxes
In the past 12 months, Eli Lilly has paid $3.06 billion in taxes.
| Income Tax | 3.06B |
| Effective Tax Rate | 18.15% |
Stock Price Statistics
The stock price has decreased by -5.86% in the last 52 weeks. The beta is 0.46, so Eli Lilly's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -5.86% |
| 50-Day Moving Average | 739.36 |
| 200-Day Moving Average | 784.95 |
| Relative Strength Index (RSI) | 72.15 |
| Average Volume (20 Days) | 3,955,870 |
Short Selling Information
The latest short interest is 7.32 million, so 0.82% of the outstanding shares have been sold short.
| Short Interest | 7.32M |
| Short Previous Month | 8.70M |
| Short % of Shares Out | 0.82% |
| Short % of Float | 0.82% |
| Short Ratio (days to cover) | 1.93 |
Income Statement
In the last 12 months, Eli Lilly had revenue of $53.26 billion and earned $13.80 billion in profits. Earnings per share was $15.29.
| Revenue | 53.26B |
| Gross Profit | 44.01B |
| Operating Income | 22.88B |
| Pretax Income | 16.86B |
| Net Income | 13.80B |
| EBITDA | 24.78B |
| EBIT | 22.88B |
| Earnings Per Share (EPS) | $15.29 |
Balance Sheet
The company has $3.55 billion in cash and $39.98 billion in debt, giving a net cash position of -$36.01 billion or -$40.12 per share.
| Cash & Cash Equivalents | 3.55B |
| Total Debt | 39.98B |
| Net Cash | -36.01B |
| Net Cash Per Share | -$40.12 |
| Equity (Book Value) | 18.35B |
| Book Value Per Share | 20.37 |
| Working Capital | 10.83B |
Cash Flow
In the last 12 months, operating cash flow was $10.94 billion and capital expenditures -$6.05 billion, giving a free cash flow of $4.88 billion.
| Operating Cash Flow | 10.94B |
| Capital Expenditures | -6.05B |
| Free Cash Flow | 4.88B |
| FCF Per Share | $5.44 |
Margins
Gross margin is 82.64%, with operating and profit margins of 42.96% and 25.91%.
| Gross Margin | 82.64% |
| Operating Margin | 42.96% |
| Pretax Margin | 31.66% |
| Profit Margin | 25.91% |
| EBITDA Margin | 46.52% |
| EBIT Margin | 42.96% |
| FCF Margin | 9.17% |
Dividends & Yields
This stock pays an annual dividend of $6.00, which amounts to a dividend yield of 0.71%.
| Dividend Per Share | $6.00 |
| Dividend Yield | 0.71% |
| Dividend Growth (YoY) | 15.31% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 37.93% |
| Buyback Yield | 0.18% |
| Shareholder Yield | 0.89% |
| Earnings Yield | 1.81% |
| FCF Yield | 0.64% |
Analyst Forecast
The average price target for Eli Lilly is $969.56, which is 14.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $969.56 |
| Price Target Difference | 14.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 17.96% |
| EPS Growth Forecast (5Y) | 32.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 16, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Oct 16, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Eli Lilly has an Altman Z-Score of 7.1 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.1 |
| Piotroski F-Score | 6 |